News

Latest News

1st March 2010 Richmond Pharmacology (RPL) will be attending this month’s 22nd Annual DIA EuroMeeting, taking place 8-10 March 2010 in Monaco, Spain. The DIA Annual EuroMeeting features more than 110 hot-topic sessions across 13 themes and attracts more than 3,000 professionals from the biopharmaceutical industry, contract service organisations, regulatory agencies, health ministries and academia, as well as patients and students worldwide. Themes are based on an integrated multidisciplinary approach that will generate interest from as many disciplines as possible. This year’s themes include: Innovation Staying in Business: How to Make Sure You Comply with All Rules and Regulations Paediatric Medicines on Their Way to Patients Decision Making: The Key to Efficient and Effective Drug Development, approval, and access Paving the Way for Advanced Therapies: Fostering New Generations of Biotechnology-Derived Medicines Challenges for Switching from Prescription to Non-Prescription Status through the Centralised Procedure Personalised Medicines: What Is It, Where Do We Stand, and Where Are We Going? Taking the European Regulatory Infrastructure Forward Risk Management The Informed Patient eHealth Pharmaceutical Sciences in 2020 Handling Clinical Trials, eSubmissions and Quality Requests Click here to download advanced programme. RPL will be exhibiting at this year’s DIA EuroMeeting to inform key decision makers in the industry of our expertise and experience in the field of Early Phase Research. The EuroMeeting is a key event in the calendar and this forum provides an ideal opportunity to meet with existing clients, network and connect with new prospective sponsors. Planning to attend? We look forward to seeing you in Monaco next month!

7th December 2009 Richmond Pharmacology is proud to announce that it will be hosting the AHPPI Winter Meeting early next month. The AHPPI is an informal cross-industry discussion group whose purpose is to address issues facing those involved in early phase drug development and to educate members through directed symposia at each of its 2 meetings per year. The Association has been in existence for over nearly 2 decades and has forged links with both other scientific societies with similar interests and with professional bodies such as the ABPI and ICR. For several years, the association has been organising joint biannual meetings with the clinical section of the British Pharmacological Society , all of which have been very successful and will continue in the future. This year’s AHPPI Annual Winter meeting will be hosted at St George’s Hospital, University of London, Tooting and will take place on 4th February 2010. We kindly invite all members of the AHPPI as well as those who are not members and keen to attend, to join us on the day. The meeting has recently been awarded 3 CPD points by the Faculty of Pharmaceutical Physicians. The topic of discussion will be “Current Advances in the Development of Vaccines and Biopharmaceuticals: A Challenge not be Sneezed at?” and there is an exciting list of key speakers already lined up for the day, namely; • Professor David Lewis, St George’s Vaccine Institute • Dr Afshan Ahmad, Vaccine Research International • Dr Simon Beddows, Health Protection Agency • Dr Azharul Mannan, Sanofi Pasteur MSD • Professor Geoff Hale, BioAnaLab • Professor John Oxford, Retroscreen Virology Ltd. • Andrew Nolan, Quintiles For further details for what’s in store for the day, please click here to view the meeting agenda. If you would like to register for this meeting; please complete our online registration form. If you would like to request more information, please email us at info@richmondpharmacology.com or complete our online enquiry form. Registrations for AHPPI members: £20.00 Registrations for non-members: £50.00

9th April 2009 Richmond Pharmacology is the FIRST and ONLY Clinical Research Organisation to become part of the UKCRC Experimental Medicines Resources Network Following an application process and review by the UKCRC Experimental Medicine Resources Review Panel, Richmond Pharmacology has become the first and only CRO to be listed on the UKCRC Experimental Medicines Resources Website. This is a big step forward in the union of commercial research and hospital based research. As the only CRO to have two hospital based clinical research centres, Richmond Pharmacology were eager to become part of this initiative. Richmond Pharmacology has for a number of years been working with academics and consultants on a variety of early phase trials involving both healthy volunteer and patient panels. The most recent successful union between Richmond Pharmacology and hospital based consultants has come in the form of the completion of a large scale Multiple Sclerosis (MS) Phase I/Phase II trial. 71 patients with MS have been included in this trial and 70 of the 71 have now completed the intensive 35 day period. The specialist knowledge and experience of the consultants we worked with, combined with our specialist knowledge and experience of early phase clinical research resulted in a team that was able to deliver a clinically excellent and efficiently run clinical trial. The application process for inclusion on the Experimental Medicines Resources Website was undertaken whilst the afore mentioned trial was underway. Our acceptance by the review panel independently coincided with conclusion of this study. However we believe that the evidence that we can add value to early phase patient trials can only help to strengthen our case for being a part of this resource site. All at Richmond Pharmacology are very excited for what the future holds and believe that this union will be good for Richmond Pharmacology, the UKCRC Experimental Medicines Resources and those in the pharmaceutical industry that make use of this resource and union. The UKCRC Experimental Medicines Resources is a new initiative and is the culmination of many years hard work of many people. Richmond is proud to be part of this initiative and hope that it is beneficial to all concerned. Please see below for further information: The UKCRC Experimental Medicines Resources is a new definitive information resource on UK experimental medicine research. It provides, for the first time, a central information repository on the UK’s capability and expertise in experimental medicine and early phase clinical trials. The new resource will act as an optimum entry point for investigators from both industry and academia seeking information about experimental medicine facilities in the UK. The new database contains up-to-date information on available expertise, resources, techniques and technologies in experimental medicine. Users of the site can search for facilities by location, health or disease category, or skills and equipment available. This web resource has been developed by the NIHR CRN CC on behalf of the UK Clinical Research Collaboration (UKCRC)